Guidelines for preventing 'dilution false negatives' in in vitro laboratory testing of the donor population

E. L. Heck, C. R. Baxter

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In this article we develop a calculation or formula for use in determining the potential dilution effect of fluids administered during patient treatment on serologic testing parameters. The formula uses basic principles of (a) fluid distribution over time from administration; (b) ratios of plasma and extravascular fluid volumes to body weight; and (c) common practices of fluid resuscitation. A dilution threshold of 50% was set using data from enzyme- linked immunosorbent assay human immunodeficiency virus antibody determinations performed on in vitro diluted seropositive serum samples. These data respond to issues raised by guidelines from the Centers for Disease Control and the U.S. Food and Drug Administration to achieve recipient safety without unnecessarily restricting the potential donor pool.

Original languageEnglish (US)
Pages (from-to)290-293
Number of pages4
JournalCornea
Volume13
Issue number4
DOIs
StatePublished - 1994

Fingerprint

United States Food and Drug Administration
Centers for Disease Control and Prevention (U.S.)
Resuscitation
Enzyme-Linked Immunosorbent Assay
Body Weight
Tissue Donors
HIV
Guidelines
Safety
Antibodies
Serum
Population
Therapeutics
Datasets
In Vitro Techniques

Keywords

  • Blood
  • Crystalloid
  • Dilution
  • Human immunodeficiency virus
  • Serology
  • Transplant

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Guidelines for preventing 'dilution false negatives' in in vitro laboratory testing of the donor population. / Heck, E. L.; Baxter, C. R.

In: Cornea, Vol. 13, No. 4, 1994, p. 290-293.

Research output: Contribution to journalArticle

@article{273a8c6dc9d849f89ac7ee99a620b1d9,
title = "Guidelines for preventing 'dilution false negatives' in in vitro laboratory testing of the donor population",
abstract = "In this article we develop a calculation or formula for use in determining the potential dilution effect of fluids administered during patient treatment on serologic testing parameters. The formula uses basic principles of (a) fluid distribution over time from administration; (b) ratios of plasma and extravascular fluid volumes to body weight; and (c) common practices of fluid resuscitation. A dilution threshold of 50{\%} was set using data from enzyme- linked immunosorbent assay human immunodeficiency virus antibody determinations performed on in vitro diluted seropositive serum samples. These data respond to issues raised by guidelines from the Centers for Disease Control and the U.S. Food and Drug Administration to achieve recipient safety without unnecessarily restricting the potential donor pool.",
keywords = "Blood, Crystalloid, Dilution, Human immunodeficiency virus, Serology, Transplant",
author = "Heck, {E. L.} and Baxter, {C. R.}",
year = "1994",
doi = "10.1097/00003226-199407000-00002",
language = "English (US)",
volume = "13",
pages = "290--293",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Guidelines for preventing 'dilution false negatives' in in vitro laboratory testing of the donor population

AU - Heck, E. L.

AU - Baxter, C. R.

PY - 1994

Y1 - 1994

N2 - In this article we develop a calculation or formula for use in determining the potential dilution effect of fluids administered during patient treatment on serologic testing parameters. The formula uses basic principles of (a) fluid distribution over time from administration; (b) ratios of plasma and extravascular fluid volumes to body weight; and (c) common practices of fluid resuscitation. A dilution threshold of 50% was set using data from enzyme- linked immunosorbent assay human immunodeficiency virus antibody determinations performed on in vitro diluted seropositive serum samples. These data respond to issues raised by guidelines from the Centers for Disease Control and the U.S. Food and Drug Administration to achieve recipient safety without unnecessarily restricting the potential donor pool.

AB - In this article we develop a calculation or formula for use in determining the potential dilution effect of fluids administered during patient treatment on serologic testing parameters. The formula uses basic principles of (a) fluid distribution over time from administration; (b) ratios of plasma and extravascular fluid volumes to body weight; and (c) common practices of fluid resuscitation. A dilution threshold of 50% was set using data from enzyme- linked immunosorbent assay human immunodeficiency virus antibody determinations performed on in vitro diluted seropositive serum samples. These data respond to issues raised by guidelines from the Centers for Disease Control and the U.S. Food and Drug Administration to achieve recipient safety without unnecessarily restricting the potential donor pool.

KW - Blood

KW - Crystalloid

KW - Dilution

KW - Human immunodeficiency virus

KW - Serology

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=0028246387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028246387&partnerID=8YFLogxK

U2 - 10.1097/00003226-199407000-00002

DO - 10.1097/00003226-199407000-00002

M3 - Article

C2 - 7924327

AN - SCOPUS:0028246387

VL - 13

SP - 290

EP - 293

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 4

ER -